Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Authors:
- Sabra L. KleinSKSabra L. Klein
- Andrew PekoszAndrew Pekosz
- Han-Sol ParkHPHan-Sol Park
- Rebecca L. UrsinRURebecca L. Ursin
- Janna R. ShapiroJSJanna R. Shapiro
- Sarah E. BennerSBSarah E. Benner
- Kirsten LittlefieldKLKirsten Littlefield
- Swetha KumarSKSwetha Kumar
- Harnish Mukesh NaikHNHarnish Mukesh Naik
- Michael J. BetenbaughMBMichael J. Betenbaugh
- Ruchee ShresthaRSRuchee Shrestha
- Annie A. WuAWAnnie A. Wu
Preprint
Abstract
Convalescent plasma is currently one of the leading treatments for COVID-19, but there is a paucity of data identifying therapeutic efficacy. A comprehensive analysis of the antibody responses in potential plasma donors and an understanding of the clinical and demographic factors that drive variant antibody responses is needed. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated by a SARS-CoV-2 virus neutralization assay using Vero-E6-TMPRSS2 cells, commercial IgG and IgA ELISA to Spike (S) protein S1 domain (Euroimmun), IgA, IgG and IgM indirect ELISAs to the full-length S or S-receptor binding domain (S-RBD), and an IgG avidity assay. Multiple linear regression and predictive models were utilized to assess the correlations between antibody responses with demographic and clinical characteristics. IgG titers were greater than either IgM or IgA for S1, full length S, and S-RBD in the overall population. Of the 126 plasma samples, 101 (80%) had detectable neutralizing titers. Using neutralization titer as the reference, the sensitivity of the IgG ELISAs ranged between 95-98%, but specificity was only 20-32%. Male sex, older age, and hospitalization with COVID-19 were all consistently associated with increased antibody responses across the serological assays. Neutralizing antibody titers were reduced over time in contrast to overall antibody responses. There was substantial heterogeneity in the antibody response among potential convalescent plasma donors, but sex, age and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody levels. One Sentence Summary: There is substantial heterogeneity in the antibody response to SARS-CoV-2 infection, with greater antibody responses being associated with male sex, advancing age, and hospitalization with COVID-19.Keywords
All Related Versions
- Published version: Journal of Clinical Investigation, 130 (11), 6141.
This publication has 29 references indexed in Scilit:
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProceedings of the National Academy of Sciences of the United States of America, 2020
- The protective potential of Fc‐mediated antibody functions against influenza virus and other viral pathogensImmunology & Cell Biology, 2020
- Sex and Gender Differences in the Outcomes of Vaccination over the Life CourseAnnual Review of Cell and Developmental Biology, 2017
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityMicrobiology and Molecular Biology Reviews, 2016
- Neutralization of Virus Infectivity by Antibodies: Old Problems in New PerspectivesAdvances in Biology, 2014
- Using the Margins Command to Estimate and Interpret Adjusted Predictions and Marginal EffectsThe Stata Journal: Promoting communications on statistics and Stata, 2012
- Comparative Evaluation of Profiles of Antibodies to Mycobacterial Capsular Polysaccharides in Tuberculosis Patients and Controls Stratified by HIV StatusClinical and Vaccine Immunology, 2012
- An immunosuppressed Syrian golden hamster model for SARS-CoV infectionVirology, 2008
- Severe Acute Respiratory Syndrome Coronavirus Gene 7 Products Contribute to Virus-Induced ApoptosisJournal of Virology, 2007
- The ORF7b Protein of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Is Expressed in Virus-Infected Cells and Incorporated into SARS-CoV ParticlesJournal of Virology, 2007